Support and Resistance Basics

What is MACD and how to read it?

How RSI can help?
RSI : 000

Stock Summary

Top Correlated Resources

AZRX


Top 10 Correlated Stocks

AZRX


In the News

12:47 13 Aug 2022 AZRX

AzurRx BioPharma to Change Corporate Name to First Wave BioPharma Today

Company to begin trading on Nasdaq under new ticker symbol, “FBWI”, effective September 22 Company to begin trading on Nasdaq under new ticker symbol, “FBWI”, effective September 22

09:20 13 Aug 2022 AZRX

3 Penny Stocks That Top Investors Buying Right Now

Which penny stocks are you watching in September 2021? Here's three for some watchlist inspiration The post 3 Penny Stocks That Top Investors Buying Right Now appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.

12:59 13 Aug 2022 AZRX

AzurRx (AZRX) Announces First Wave Bio Acquisition for $229M

AzurRx BioPharma (AZRX) acquires First Wave Bio for $229 million. Following the acquisition, the company is set to rename itself as First Wave BioPharma.

07:30 13 Aug 2022 AZRX

AzurRx BioPharma CEO Issues Letter to Shareholders Regarding Recent Acquisition of First Wave Bio and Creation of First Wave BioPharma

BOCA RATON, Fla., Sept. 14, 2021 (GLOBE NEWSWIRE) -- AzurRx BioPharma, Inc. (NASDAQ:AZRX), (“First Wave BioPharma” or the “Company”), a clinical-stage biopharmaceutical company specializing in the development of targeted, non-systemic therapies for gastrointestinal (GI) diseases, today issued a letter to its shareholders from James Sapirstein, President, Chief Executive Officer and Chairman, regarding its recently announced merger with First Wave Bio, Inc. and adoption of the First Wave BioPharma name. The full text of the letter, which has also been posted to the Company's website, is as follows:

04:40 13 Aug 2022 AZRX

AzurRx BioPharma, Inc. (AZRX) CEO James Sapirstein on First Wave Bio Acquisition - Conference Call Transcript

AzurRx BioPharma, Inc. (AZRX) CEO James Sapirstein on First Wave Bio Acquisition - Conference Call Transcript

09:19 13 Aug 2022 AZRX

AzurRx BioPharma Announces Reverse Merger With First Wave Bio

AzurRx BioPharma Inc (NASDAQ: AZRX) has agreed to acquire First Wave Bio Inc in a stock and cash transaction valued at $229 million, including milestone payments.  First Wave Bio is a clinical-stage biotechnology company specializing in developing gut-targeted, small molecule therapies for autoimmune inflammatory bowel diseases (IBD).

06:00 13 Aug 2022 AZRX

AzurRx BioPharma Announces Acquisition of First Wave Bio and its Proprietary Niclosamide Formulations Targeting Multi-Billion Dollar Inflammatory Bowel Disease Indications

AzurRx BioPharma to be renamed “First Wave BioPharma” and trade under new NASDAQ ticker symbol, “FWBI”

12:45 13 Aug 2022 AZRX

AzurRx BioPharma Announces Reverse Stock Split

Common Stock Will Begin Trading on Split-Adjusted Basis on September 13, 2021 Common Stock Will Begin Trading on Split-Adjusted Basis on September 13, 2021

08:30 13 Aug 2022 AZRX

AzurRx BioPharma Activates New Clinical Trial Sites in India for Phase 2 RESERVOIR Trial Evaluating Niclosamide for the Treatment of COVID-19 Gastrointestinal Infections

Phase 2 placebo-controlled clinical trial to confirm safety of FW-1022 and investigate its ability to remove SARS-CoV-2 virus from the GI tract Phase 2 placebo-controlled clinical trial to confirm safety of FW-1022 and investigate its ability to remove SARS-CoV-2 virus from the GI tract

08:30 13 Aug 2022 AZRX

AzurRx BioPharma Announces Positive Results from Independent Data Monitoring Committee Review of Safety Data from Part 1 of RESERVOIR Phase 2 Clinical Trial of Niclosamide for the Treatment of COVID-19 Gastrointestinal Infections

Review of Interim Safety Data Concluded with Favorable Recommendation to Continue RESERVOIR Trial as Planned

Financial details

Company Rating
Neutral
Market Cap
271.08M
Income
32671.48B
Revenue
0
Book val./share
0.9
Cash/share
1.03
Dividend
-
Dividend %
-
Employees
12
Optionable
No
Shortable
Yes
Earnings
13 Aug 2019
P/E
0
Forward P/E
-
PEG
-
P/S
-
P/B
3.83
P/C
0.14
P/FCF
-0.95
Quick Ratio
1.25
Current Ratio
1.33
Debt / Equity
0.04
LT Debt / Equity
0.04
-
-
EPS (TTM)
-11.66M
EPS next Y
-
EPS next Q
-
EPS this Y
87217369.15%
EPS next Y
-
EPS next 5Y
-
EPS last 5Y
-
Revenue last 5Y
-
Revenue Q/Q
-
EPS Q/Q
-14.47%
-
-
-
-
SMA20
-42.31%
SMA50
-58.33%
SMA100
-86.73%
Inst Own
0%
Inst Trans
0%
ROA
-237148578%
ROE
-397667016%
ROC
-3609716.16%
Gross Margin
-
Oper. Margin
-
Profit Margin
-
Payout
-
Shs Outstand
78.58M
Shs Float
91.82M
-
-
-
-
Target Price
-
52W Range
2.68-26.3
52W High
-99.44%
52W Low
-92.68%
RSI
35.1
Rel Volume
2.8
Avg Volume
713.03K
Volume
2M
Perf Week
-6.57%
Perf Month
-51.33%
Perf Quarter
-
Perf Half Y
-90.79%
-
-
-
-
Beta
1.51094
-
-
Volatility
0.01%, 0.06%
Prev Close
6.16%
Price
0.1465
Change
5.02%

Financial Performance

Yearly Fundamentals Overview

Last date of statement is 2020-12-31

Metric History 2016-12-312017-12-312018-12-312019-12-31 2020-12-31
Revenue per share
00000
Net income per share
-22.43-10.44-8.77-6.77-5.9M
Operating cash flow per share
-6.97-6.76-7.04-6.26-2.03
Free cash flow per share
-6.99-6.79-7.08-6.27-2.03
Cash per share
2.730.540.720.080
Book value per share
4.941.562.92.06-0.48
Tangible book value per share
-0.6-1.61.28-0.30
Share holders equity per share
4.941.562.92.06-0.48
Interest debt per share
9.371.220.230.911.06M
Market cap
29.27M36.99M31.34M20.38M80.81M
Enterprise value
27.65M36.83M30.48M21.81M81.41M
P/E ratio
-2.01-3.33-2.32-1.340
Price to sales ratio
00000
POCF ratio
-6.45-5.15-2.88-1.45-7.2
PFCF ratio
-6.44-5.13-2.87-1.45-7.2
P/B Ratio
9.1122.277.014.41-30.6
PTB ratio
9.1122.277.014.41-30.6
EV to sales
00000
Enterprise value over EBITDA
-4.69-3.95-2.41-1.590
EV to operating cash flow
-6.1-5.13-2.8-1.55-7.25
EV to free cash flow
-6.08-5.1-2.79-1.55-7.25
Earnings yield
-0.5-0.3-0.43-0.74-404.31K
Free cash flow yield
-0.16-0.2-0.35-0.69-0.14
Debt to equity
00000
Debt to assets
0.520.70.40.481.57
Net debt to EBITDA
0.270.020.07-0.10
Current ratio
1.270.791.60.80.51
Interest coverage
-1.12-11.52-131.88-33.98-4.53
Income quality
0.310.650.80.920
Dividend Yield
00000.1
Payout ratio
00000
Sales general and administrative to revenue
00000
Research and developement to revenue
00000
Intangibles to total assets
0.530.610.330.590.21
Capex to operating cash flow
000.0100
Capex to revenue
00000
Capex to depreciation
-0.02-0.04-0.07-0.02-0.11
Stock based compensation to revenue
00000
Graham number
49.9319.1623.9117.717.96K
ROIC
-1.5-3.36-3-3.194.72B
Return on tangible assets
-4.63-5.24-2.72-4.21-4.14B
Graham Net
-1.61-2.270.32-0.950
Working capital
623.13K-526.51K1.8M-877.35K-7.68K
Tangible asset value
-390.57K-1.7M1.98M-676.53K-7.68K
Net current asset value
-576.87K-1.87M1.8M-877.35K-7.69K
Invested capital
0.050.250.060.35-0.23
Average receivables
1.8M1.87M2.9M2.64M0
Average payables
1.64M1.46M2.21M2.22M1.11M
Average inventory
00000
Days sales outstanding
00000
Days payables outstanding
00000
Days of inventory on hand
00000
Receivables turnover
00000
Payables turnover
00000
Inventory turnover
00000
ROE
-4.54-6.68-3.03-3.2912.37M
Capex per share
-0.02-0.03-0.04-0.010

Quarterly Fundamentals Overview

Last date of statement is 2021-06-30 for Q2

Metric History 2020-06-302020-09-302020-12-312021-03-31 2021-06-30
Revenue per share
00000
Net income per share
-1.680-11.66M-1.39-1.19
Operating cash flow per share
-0.48-0.96-2.1-0.92-0.72
Free cash flow per share
-0.48-0.96-2.1-0.92-1.88
Cash per share
0.354.062.162.171.03
Book value per share
-0.285.02-0.942.60.9
Tangible book value per share
-2.083.24-2.741.750.31
Share holders equity per share
-0.285.02-0.942.60.9
Interest debt per share
2.780.462.08K0.080.07
Market cap
25.38M19.92M27.18M74.17M64.06M
Enterprise value
29.88M8.63M21.72M62.55M56.53M
P/E ratio
-1.35-937.150-2.41-1.73
Price to sales ratio
00000
POCF ratio
-18.89-7.39-4.61-14.62-11.39
PFCF ratio
-18.92-7.39-4.61-14.62-4.36
P/B Ratio
-31.831.42-10.295.159.1
PTB ratio
-31.831.42-10.295.159.1
EV to sales
00000
Enterprise value over EBITDA
-13.27-2.410-8.29-6.18
EV to operating cash flow
-22.24-3.2-3.69-12.33-10.05
EV to free cash flow
-22.27-3.2-3.69-12.33-3.85
Earnings yield
-0.190-1.2M-0.1-0.14
Free cash flow yield
-0.05-0.14-0.22-0.07-0.23
Debt to equity
00000.04
Debt to assets
1.120.161.570.20.49
Net debt to EBITDA
-23.1601.540.82
Current ratio
0.214.390.513.681.33
Interest coverage
-1.040-4.53K-1.6K-3.14K
Income quality
0.29507.500.660.61
Dividend Yield
00.020.300
Payout ratio
0-76.79000
Sales general and administrative to revenue
00000
Research and developement to revenue
00000
Intangibles to total assets
0.730.30.210.260.33
Capex to operating cash flow
00000
Capex to revenue
00000
Capex to depreciation
0-0.02000
Stock based compensation to revenue
00000
Graham number
3.280.4615.73K9.024.91
ROIC
3.1804.72M-0.57-1.27
Return on tangible assets
-2.570-4.14M-0.58-1.01
Graham Net
-2.353.12-3.391.590.17
Working capital
-6.01M8.91M-7.68M9.6M2.16M
Tangible asset value
-5.83M9.09M-7.68M9.68M2.43M
Net current asset value
-6.06M8.88M-7.69M9.59M1.88M
Invested capital
-6.880.01-0.230.030.08
Average receivables
302.13K261.17K0501.66K0
Average payables
1.52M1.45M1.56M1.44M2.95M
Average inventory
00000
Days sales outstanding
00000
Days payables outstanding
00000
Days of inventory on hand
00000
Receivables turnover
00000
Payables turnover
00000
Inventory turnover
00000
ROE
5.89012.37M-0.53-1.32
Capex per share
00000

Something similar

Top Correlated Stocks
Similar Market Cap